Antares Pharma Announces FDA Acceptance of Anturol NDA for Filing
Links shared publicly online about this topic.
- 317total visits
Antares Pharma Announces FDA Acceptance of Anturol NDA for Filing
Anturol (oxybutynin) is a new drug in development for the treatment of overactive bladder. Anturol information includes news, clinical trial results and side effects.
View full resource at drugs.com
Tags: Overactive Bladder Medication, Drug, Pharma, FDA, Ditropan, Gelnique, Oxytrol
Most Recently Shared on May 5, 2011 at 12:15 am By:
Antares Pharma Announces FDA Acceptance of Anturol NDA for Filing: EWING, N.J.--(BUSINESS WIRE)--Apr 8, 20... http://bit.ly/iE4oV3 #drug
Advertisement
